“South Africa’s crackdown on illegally compounded GLP-1 weight-loss medicines has disrupted access for potentially hundreds of thousands of people who had been relying on cheaper alternatives to registered prescription treatments. Health experts and regulators warn that patients should not turn to unregistered medicines, even as concerns about the high cost of authorized treatments continue to make access difficult.”
South Africa’s rapidly expanding market for weight-loss medicines is facing a major safety and affordability challenge after regulatory and legal action against pharmacies involved in the unlawful compounding of GLP-1 medicines left potentially hundreds of thousands of patients searching for alternatives. The development has highlighted a difficult tension within modern medicine: patients want access to effective treatments for obesity and related conditions, but regulators must ensure that medicines reaching the public are manufactured, tested, labelled and dispensed safely.
According to a report by SABC News published on 3 October, recent action against pharmacies illegally compounding GLP-1 weight-loss medicines may have affected as many as 300,000 South Africans. Obiflex chief executive Shaun Barns said patients who can no longer obtain compounded products face a difficult choice between seeking potentially dangerous products from unregulated sources and paying substantially more for registered, doctor-prescribed medicines.
The issue centres on a class of medicines known as GLP-1 receptor agonists, which have become increasingly prominent in the treatment of type 2 diabetes and obesity. Medicines containing compounds such as semaglutide and tirzepatide can influence blood-glucose regulation, appetite and feelings of fullness. Their effectiveness has generated enormous public interest, while high demand has also created opportunities for illegal and poorly regulated products.
South Africa’s medicines regulator, the South African Health Products Regulatory Authority (SAHPRA), has been increasingly active in policing this market. In May 2026, SAHPRA and the South African Pharmacy Council announced enforcement action against unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing semaglutide, tirzepatide or combinations of the two. The authorities said an inspection of a Pretoria pharmacy uncovered products being manufactured and supplied under the pretext of compounding but outside the legal framework.
The regulator reported several serious deficiencies, including problems involving manufacturing conditions, analytical testing, sterile preparation, equipment and pharmacovigilance. Such shortcomings are important because injectable medicines require particularly careful manufacturing and quality control. Contamination, incorrect concentration or impurities can potentially expose patients to serious harm.
The South African regulator has also stressed that consumers need to distinguish between registered medicines and products marketed through informal or unauthorised channels. SAHPRA’s guidance on semaglutide states that registered products must meet regulatory requirements and that consumers should be cautious about medicines obtained outside accredited pharmaceutical channels.
The affordability problem, however, remains central to the debate. SABC reported that registered prescription alternatives can cost approximately R4,000 to R6,000, a price that many patients may struggle to afford. For people who have come to rely on cheaper compounded products, the regulatory crackdown therefore creates an immediate financial problem even if the underlying objective is to protect patient safety.
This creates an uncomfortable situation for healthcare professionals. Doctors may have patients who believe that GLP-1 medicines are essential to their weight-management journey, but the doctor must also consider whether a particular product is properly registered, appropriately prescribed and manufactured according to required standards.
Barns warned that patients who turn to illicit medicines may be exposed to significant risks. According to the SABC report, he said some illegally obtained products could have inaccurate doses, with labels potentially differing substantially from the actual amount of medicine contained in a product. That is particularly concerning with prescription medicines where dosage must be carefully controlled.
SAHPRA’s concerns are not limited to weight-loss products themselves. The regulator has repeatedly warned about falsified, compounded and substandard GLP-1 products being sold through informal channels. Its official guidance explains that semaglutide medicines have specific registered indications and that medicines should not simply be purchased from websites or other unverified sources because they appear cheaper or promise rapid results.
At the same time, South Africa’s legitimate pharmaceutical market is changing. The expiry of patent protection for semaglutide has opened the door to greater competition. In July, India’s Sun Pharmaceutical Industries received approval to manufacture and sell a generic version of semaglutide in South Africa, potentially creating greater competition in the market.
SAHPRA has also been reviewing additional generic semaglutide applications. Reuters reported in July that the regulator was reviewing multiple applications for generic versions of semaglutide following the opening of the market to greater competition. Increased competition could eventually improve affordability, although it does not automatically mean that medicines will become immediately inexpensive.
Novo Nordisk has also introduced a lower-cost authorised semaglutide product in South Africa. Reuters reported that the company planned to launch Extensior, an authorised copy of Ozempic containing semaglutide, at a lower price than the branded medicine. The move demonstrates how manufacturers and regulators are responding to the growing demand for affordable GLP-1 therapies.
However, affordability cannot be separated from medical appropriateness. SAHPRA’s semaglutide information notes that Ozempic is registered in South Africa for adults with type 2 diabetes and cardiovascular-risk reduction in specified patients, but is not registered specifically for weight loss. This distinction is important because public discussion frequently uses brand names interchangeably with obesity treatment, even though regulatory indications can differ.
For patients, the safest approach is therefore to obtain weight-management medicines through a qualified healthcare professional and a legitimate pharmacy. People considering GLP-1 treatment should discuss their medical history, current medicines, treatment objectives and potential side effects with a doctor rather than relying on social-media advertisements or informal suppliers.
The controversy also illustrates a broader challenge facing South Africa’s healthcare system. Demand for modern medicines can develop faster than the healthcare system’s ability to make those medicines affordable and widely accessible. When legitimate products remain expensive, patients may search for cheaper alternatives. If those alternatives operate outside the regulatory system, however, the pursuit of affordability can create new medical risks.
The long-term solution is unlikely to be enforcement alone. Strong regulation is necessary to prevent unsafe products from reaching patients, but greater competition among authorised manufacturers, transparent pricing and improved access to evidence-based treatment are also important. The arrival of generic semaglutide products could help address some of these pressures if competition translates into meaningful price reductions.
The current crackdown should therefore be understood as both a medicine-safety issue and an access-to-healthcare issue. Regulators have a responsibility to prevent unsafe and illegally manufactured medicines from entering the market, while policymakers and the pharmaceutical industry face pressure to ensure that effective treatments do not remain financially inaccessible to large sections of the population.
For the hundreds of thousands of South Africans affected by the disruption of compounded GLP-1 supplies, the immediate message is clear: switching to an unverified product simply because it is cheaper may create serious health risks. Instead, patients should speak to healthcare professionals about registered alternatives and available treatment options.
South Africa’s weight-loss medicine market is entering a new phase. Greater competition, generic medicines and authorised lower-cost products could eventually improve access, while stronger enforcement should reduce the availability of unsafe alternatives. The challenge will be ensuring that these developments work together so that patients can access effective medicines without being forced to choose between unaffordable treatment and potentially dangerous products.
